Reckamp, K. L., Lin, H. M., Cranmer, H., Wu, Y., Zhang, P., Kay, S., Walton, L. J., Shen, J., Popat, S., & Camidge, D. R. (2022). Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase–positive non–small cell lung cancer using data from ALEX and final results from ALTA-1L. Current Medical Research and Opinion, 38(9), 1587–1593. https://doi.org/10.1080/03007995.2022.2100653
Reckamp, K. L., Lin, H. M., Cranmer, H., Wu, Y., Zhang, P., Walton, L. J., Kay, S., Cichewicz, A., Neupane, B., Fahrbach, K., Popat, S., & Camidge, D. R. (2022). Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer. Future Oncology, 18(20), 2499–2510. https://doi.org/10.2217/fon-2022-0194
Kay S, Strickson A, Puelles J, Selby R, Benson E, Tolley K. (Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Diabetes Therapy , 8(2):251–273
Kay S, (2016). Boosting A Modeller’s Armoury: Pursuing Realistic And Efficient Competing Risk Health Economic Models 19th Annual European International Society for Pharmacoeconomics and Outcomes Research Congress; Vienna
Kay S, Kay J. (2015). Health Economic Programming Using Royston-Parmar “Hazard Rate” Models: Providing Flexibility and Speed for Event Modelling in Cohort and DES Models.. 18th Annual European International Society for Pharmacoeconomics and Outcomes Research Congress, Milan
Tolley K, Strickson A, Kay S, Benson E, Selby R. (2014). A Decision-Focused Mixed Treatment Comparison (MTC) Of Alternative DPP-4 Inhibitors Used In Combination With Metformin Or A Sulfonylurea For The Treatment Of Type 2 Diabetes Mellitus. 17th Annual European International Society for Pharmacoeconomics and Outcomes Research Congress, Amsterdam
Kay S, Ferreira A. (2014). Mapping the 25-item National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) to EQ-5D utility scores.Ophthalmic Epidemiol 21(2):66-78
Kay S, Tolley K, Colayco D, Khalaf K, Anderson P, Globe D. (2013). Mapping EQ-5D utility scores from the Incontinence Quality of Life Questionnaire among patients with neurogenic and idiopathic overactive bladder. Value In Health 16(2): 394-402.
Virchow J, Kay S, Demoly P, Mullol J, Canonica W, Higgins V. (2011). Impact of ocular symptoms on quality of life (QoL), work productivity and resource utilisation in allergic rhinitis patients. J Med Econ 14(3): 305-14
Small M, Anderson P, Vickers A, Kay S, Fermer S. (2011). Importance of inhaler-device satisfaction in asthma treatment: Real-world observations of physician-observed compliance and clinical/patient-reported outcomes. Advances in Therapy 28(3): 202-212
Small M, Vickers A, Anderson P, Kay S. (2010). The Patient-Physician Partnership in Asthma: Real-World Observations Associated with Clinical and Patient-Reported Outcomes. Advances in Therapy 27(9):591-599
Gueron B, Demoly P, Kay S, Small M. (2010). Do Patients on Intra-nasal fluticasone furoate, mometasone furoate and fluticasone propionate Experience Similar Numbers of Symptom Free Days and Quality of Life? A study in 3 European countries European. Academy of Allergy and Clinical Immunology Congress, London
Thomas M, Kay S, Pike J, Williams A, Rosenzweig J, Hillyer E, Price D. (2009). The Asthma Control Test (ACT) as a Predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Primary Care Respiratory Journal 18(1): 41-49
Higgins V, Kay S, Small M. (2007). Physician and patient survey of allergic rhinitis: methodology. Allergy 62 (S.85): 6-8
Scadding G, Williams A, Kay S, Bousquet J. (2007). Impact of allergic rhinitis on patients’ quality of life in five European countries. European Academy of Allergy/Clinical Immunology Annual Meeting, Gὅteborg, Sweden.
Bousquet J, Williams A, Kay S, Scadding G. (2007). Physician and patient perception differ for symptoms assocated with allergic rhinitis (AR) in five European countries; European Academy of Allergy/Clinical Immunology Annual Meeting, Gὅteborg, Sweden.
Dalal A, William A, Kay S. (2007). Do allergic rhinitis patients achieve twenty-four hour symptom control? American Academy of Allergy, Asthma & Immunology Conference, San Diego
William A, Schatz, Kay S. (2007). Physician and patient perception differ for symptoms associated with allergic rhinitis, American Academy of Allergy, Asthma & Immunology Conference, San Diego
Turk F, Kay S, Higgins V. (2005). The economic and human impact of poor control in patients with severe persistent allergic ashma: results from a multinational study. British Thoracic Society Annual Conference, London
Williams A, Kay S, Kennedy-Martin T. (2004). Detrimental Impact Of Symptoms On The Quality Of Life Of (Asthma) Patients Across Severity Levels. American Thoracic Society International Conference, Orlando
Mὓllerova H, Benford M, Kay S, Davis K. (2004). COPD in Primary Care – International Survey DSP III European Respiratory Society Annual Conference, Glasgow
Williams A, Kay S. (2003). Impact and Economic Burden Observed in Asthma Patients Considered as Mild. European Respiratory Society Annual Conference, Vienna
Draffan L, Karavali M, Kay S. (2001). Chronic Obstructive Pulmonary Disease – The Patient Perspective. European Respiratory Society Annual Conference, Berlin
Clark K, Kay S, Sefton M. (2001). When Are Nash Equilibria Self-Enforcing? An Experimental Analysis, International Journal of Game Theory, 29 (4), 495-515
Brice R, Mellor P, Kay S. (2000). Choice-Adapted Preference Modelling. Sawtooth Software Annual Conference, South Carolina
Young A, Topham C, Moore J, Turner J, Wardle J, Downes M, Evans V, Kay S (1999). A patient preference study comparing raltitrexed (‘Tomudex’) and bolus or infusional 5-fluorouracil regimens in advanced colorectal cancer: influence of side-effects and administration attributes. European Journal of Cancer Care 8(3): 154-161